MicroRNAs (miRNAs) are a family of 19-24 nucleotide noncoding RNAs (ncRNAs) with posttranscriptional regulatory functions. Increasing evidences from the literature show that miRNAs play a pivotal role in human tumorigenesis. Many studies have addressed the role of miRNAs in normal hematopoiesis, giving an interpretative key to the aberrancies of expression observed in human hematological malignancies. Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype. Here we review the main studies investigating the role of miRNAs and UCRs in both normal hemopoiesis and hematological malignancies, and identify the molecular, clinical and therapeutic implications of these recent findings.
Introduction
MicroRNAs (miRNAs) are 19-24 nucleotide (nt) noncoding RNAs (ncRNA) which regulate the expression of target mRNAs both at transcriptional and translational level by perfect (in plants) or partial (in mammals) base-pairing, mainly at the 3 0 -untranslated region (3 0 -UTR) of the target messenger. [1] [2] [3] Initially transcribed as long, capped and polyadenylated primary precursors (pri-miRNA) by RNA polymerase II, 4, 5 pri-miRNAs are cleaved into a hairpin-shaped 70-100 nt precursor (called pre-miRNA), by a ribonuclease III called Drosha and the dsDNA binding protein DGCR8/Pasha 6 ( Figure 1 ). In order for the final processing to the mature miRNA to occur, the nuclear export factor exportin 5/Ran GTP 7, 8 translocates pre-miRNAs from the nucleus to the cytoplasm, where another ribonuclease III, called Dicer, in association with a dsRNA-binding protein partner named TRBP (transactivation-responsive RNA-binding protein) processes pre-miRNAs into a 19-24 nt miRNA duplex. 9, 10 A large protein complex called RISC (RNA-induced silencing complex) binds to the duplex and determines the fate of the miRNA and its target mRNA. The strand of the miRNA duplex which remains stably associated with RISC, represents the mature miRNA and drives RISC to the target mRNAs inducing its cleavage in case of perfect miRNA:mRNA base pair complementarity (mechanism described as predominant in plants), or to its translational silencing (predominant mechanism in Caenorhabditis elegans, Drosophila melanogaster and mammals), although also in case of imperfect base pairing a reduction of the target mRNA has been described 11, 12 ( Figure 1) . Recently, the physiologic roles for miRNAs have started being elucidated by showing that their functions span from development, differentiation, cell cycle regulation 9, [13] [14] [15] to aging and metabolism. [16] [17] [18] Consequently miRNA deregulation has been found in many different human diseases, including cancer, diabetes, immuno-or neurodegenerative disorders. 19 The development of tools able to detect the expression of miRNAs has shown that the miRNome (defined as the full spectrum of miRNAs expressed in a particular cell type) is differentially expressed in normal as well as in neoplastic tissues. A unique and specific miRNA signature is able to distinguish between different normal tissues, and more interestingly characterizes different types of cancers. 20 The tumor specificity of this signature harbors several diagnostic, prognostic and therapeutic implications, which justify the efforts made by many groups in decoding the miRNome and understanding the molecular functions of the aberrantly expressed miRNAs. Recently, a new class of noncoding RNAs (ncRNAs), the ultraconserved genes (UCGs) have been implicated in human tumorigenesis. 21 Ultraconserved regions (UCRs) are a subset of very conserved sequences which are strictly conserved among orthologous regions of the human, rat and mouse genomes, 22 and due to their noncoding nature, have been considered for long time as 'dark matter' of the human genome. 23 Recent finding proved the transcriptional activity of the majority of these regions and therefore named these as ultraconserved genes (UCGs, or as transcribed UCRs); furthermore, the identification of regulatory functions of miRNAs on cancer-associated UCGs 21 opens new investigational scenarios with possible clinical implications.
miRNAs in hematopoiesis
The role of miRNAs has been extensively studied in human hematopoiesis. The involvement of miRNAs in normal human hematopoiesis has been studied by many groups, and is summarized in Figure 2 . A new database which identifies miRNAs that control hematopoietic differentiation through a translational control of mRNAs important in hematopoiesis has predicted miR-128a and -181a as regulating the differentiation of the multipotent progenitor cell (MPP) in both common myeloid (CMP) and common lymphoid (CLP) progenitors, whereas miR-146 blocks lymphoid differentiation and miR-155, -24a and -17 myeloid differentiation at an early stage. 24 
miRNAs in myeloid differentiation
During myeloid differentiation, miR-16, -103 and -107 have been predicted to block early granulocyte/macrophage commitment, 24 while miR-223 exerts a pivotal role by targeting NFI-A and C/EBPalpha, two regulators of human granulopoiesis, 25 able to respectively silence or activate the expression of miR-223, by binding to its promoter region. Retinoic acid-induced differentiation favors the binding of C/EBPalpha and results in an upregulation of miR-223, which in turn, targets NFI-A mRNA. An increased differentiation of acute promyelocytic leukemic cells is observed both by NFI-A silencing with silencing RNA techniques and by ectopic expression of miR-223, while silencing of miR-223 inhibits the differentiation response to retinoic acid. 25 More recently miR-17-5p, -20a and -106a (encoded by the paralogous clusters miR-17-92 and miR-106a- 
MicroRNAs in leukemias
M Fabbri et al 92) have also shown an inhibitory effect on monocytic differentiation and maturation, by targeting the transcription factor acute myeloid leukemia 1 (AML1), and inducing downregulation of the macrophage colony-stimulating factor receptor. 26 Intriguingly AML1 can negatively regulate the expression of these miRNAs by binding to the promoter region of the two clusters. 26 In erythroid differentiation, a progressive downregulation of miR-150, -155, -221 and -222 occurs, while miR-451 and miR-16 levels increase at late stages of erythropoiesis. Interestingly some miRNAs (miR-339 and -378) show a biphasic regulation during erythroid commitment of the hematopoietic stem cell. 27, 28 A panel of miRNAs (miR-10a, -126, -106, -10b, -17 and -20) is also downregulated during megakaryocytopoiesis; 29 in particular miR-130a, whose expression is also reduced as the megakaryocytic differentiation proceeds, targets the transcription factor MAFB, involved in the activation of GPIIB promoter, an important protein for platelet physiology. 29 
miRNAs in lymphoid differentiation
Ectopical expression of miR-150 (which is selectively expressed in mature, resting B and T cells, but not in their progenitors 30 ), in murine hematopoietic stem and progenitor cells significantly reduced mature B-cell levels in the circulation, spleen and lymph nodes, with no effect in the levels of T-and myeloid cells. 31 The observed effect on B lymphopoiesis could be explained with a block in the transition from pro-B to pre-B cell stage. 31 These results were confirmed by miR-150 transgenic (TG) and knockout (KO) mice models which supported the stage-specific expression of this miRNA during lymphocyte development, and the expansion of the mature B-cell subset called B1 (responsible for the production of a high fraction of the 'natural' antibodies in the blood), with consequent enhancement of the humoral immune response. 32 The profound impairment of lymphocyte development associated with miR-150 ectopic expression is due to the miRNA-induced apoptosis of pro-B cells. 32 At a molecular level, the effects of miR-150 in hemopoiesis are mediated by c-MYB, a directly targeted transcription factor. 32 Interestingly the findings that miR-150 controls c-Myb expression in vivo in a dose-dependent manner over a very narrow range, and that the observed 30-35% reduction of c-Myb protein levels after overexpression of the miRNA can explain the dramatic phenotype observed in the miR-150 TG mice, 32 could have a huge impact on a larger context of gene delivery and therapeutic approaches. Another miRNA important in lymphopoiesis is miR-155. By transfecting human CD34 þ peripheral blood stem cells with miR-155, Georgantas et al. 24 showed that miR-155 greatly reduces both myeloid and erythroid colony formation. These results were confirmed in TG and KO mice models of miR-155. A polyclonal preleukemic pre-B-cell proliferation followed by full-blown B-cell malignancy was described in the first TG mouse model, characterized by B cell-targeted overexpression of miR-155, 33 revealing that deregulation of this miRNA could occur as an early event in leukemogenesis. Two different groups have developed miR-155 KO mice models and they both identified a critical role of this miRNA in the immune response. 34, 35 MiR-155 controls the germinal center (GC) reaction in the context of a T celldependent antibody response, at least in part by affecting the level of cytokine production, since BIC/miR-155 À/À cells produce more interleukin-4 and less interferon-g, both hallmarks of a T H 2 differentiation. 34 Among the predicted targets of miR-155 which are deregulated in the KO mouse model, the transcription factor c-MAF could explain why BIC-deficient T H cells are intrinsically biased toward T H 2 differentiation. 35 Moreover KO mice showed a compromised ability of dendritic cells (DC) to activate T cells, due to defective antigen presentation or costimulatory functions. 35 By cloning approximately 150 miRNAs from murine bone marrow, Chen et al. 36 identified miR-181a, -223 and -142 as preferentially expressed in hematopoietic tissue. A paucity of T lymphocytes and increased B cells was observed after ectopic expression of miR-181a (whether this effect results from an increased commitment of stem cells in the B-lineage or from a higher survival rate of B cells is still undetermined). Recently a new possible explanation to the paucity of T cells after miR181a overexpression has raised. Forced expression of miR-181a in the DP stage of thymocyte development (defined by the expression of CD4 and CD8 coreceptors) could result in retention of positively selected thymocytes in the thymus and in an apparent decrease in peripheral T cells. 37 This effect might be a consequence of decreased levels of CD69 on positively selected thymocytes, which negatively impacts the egress of lymphocytes from lymphoid tissues, including the thymus. 38 Moreover miR-181a targets T-cell receptor (TCR) and BCL-2. 37 Reduced levels of TCR shift the threshold for positive and negative selection, while the targeting of BCL2 upon positive selection would result in cell death. Moreover increased miR181a expression in mature T cells increases sensitivity to peptide antigens. 39 Ectopic expression of miR-223 and -142 induced a 30-50% increase in the proportion of the T-lineage cells, but not of the B-lineage or myeloid cells, despite these miRNAs are highly expressed in myeloid lineages (and, for miR-142, in B cells too). 36 Notably, a different pattern of expression of these miRNAs was observed in human hematopoiesis with respect to the mouse model. 40 A deregulation of miRNAs throughout murine hematopoietic development included miR-146 (upregulated in T H 1 cells) and miR-150 (downregulated in response to T-cell stimulation in T H 1 and T H 2 lymphocytes). 30 Conversely to what has been described in human, in murine hematopoiesis, miR-150 is upregulated during B-cell maturation. 30 The progressively increasing knowledge of the physiologic implications of miRNAs in human hematopoiesis represents a mandatory background to properly design future studies aimed at identifying and correcting aberrancies of the miRNome in hematological malignancies.
miRNAs are frequently located in cancer associated genomic regions
The first clue of a possible general involvement of miRNAs in cancer was the identification of a genome-wide correlation between the genomic localizations of miRNAs and cancer associated genomic regions (CAGRs 41 ; for extensive review on chromosomal rearrangements and miRNAs see Calin et al.
42
). CAGRs include minimal regions of amplification, loss of heterozygosity (LOH), common breakpoint regions in or near oncogenes (OGs) and tumor suppressor genes (TSGs), and fragile sites (FRAs), which are preferential sites of chromatid exchange, translocation, deletion, amplification or integration of plasmid DNA and tumor-associated viruses. Overall more than 50% of the 186 miRNAs that we mapped are located in CAGRs.
In particular, about 19% are located inside or close to FRAs, whereas another 43% map in the regions of genomic amplification or LOH. Interestingly some miRNAs are placed in 'orphan' FRAs, meaning FRAs frequently deleted in cancers but with no well identified TSG (for example, miR-29a and miR29b-1, located in FRA7H). A recently increasing evidence of a role of these miRNAs as oncosuppressors, both in solid 43, 44 and hematological malignancies, 45 identifies in members of the miRNA-family at least some of these TSGs. Another example is miR-142, which is located in FRA17B, a target of HPV16 integration in cervical tumors. 41 Interestingly miR-142 is also located very close (50 nt of distance) from the t(8;17) breakpoint region. The translocation creates a pre-miR-142/MYC fusion product, by bringing MYC 4-nt downstream of the 3 0 end of premiR-142, and prevents the recognition of pre-miR-142 transcript as a miRNA precursor, therefore determining accumulation of fusion transcripts and overexpression of MYC. 46 MiR-180 is located about 1 kb from MN1, a gene inactivated by the translocation t(4;22) in meningioma. The same translocation could lead to an abnormal miR-180 silencing. 41 Other examples of association of miRNA-CAGRs include the minimal amplicon around the MALT gene in aggressive marginal zone lymphoma, which hosts miR-122a (also located at about 160 kb from the breakpoint region of t(11;18) in mucosa-associated lymphoid tissue lymphoma 47 ). A rearrangement of miR-125b-1, juxtaposed to the immunoglobulin heavy chain locus was described as a possible early step in leukemogenesis, in a B-cell acute lymphocytic leukemia (B-ALL) patient. 48 An association has been described also between miRNA locations and HOX genes (encoding transcription factors important for normal development and cancerogenesis), creating an even more robust connection between miRNAs and cancer. 41 By using highresolution array comparative genomic hybridization (aCGH), another group showed that in human cancers genomic alterations occur at high frequency in miRNA loci. 49 Another extensive analysis on 60 cell lines identified CAGR-located oncogenic miRNAs. 50 Also in mice, clusters of miRNAs have been found in close proximity to murine CAGRs and sites of retroviral integration. 51 The finding of miRNAs nonrandomly located in CAGRs in different genomes, further suggests the involvement of these ncRNAs in cancer and has given rise to many studies aimed at investigating the nature of this correlation.
miRNAs as oncogenes in hematological malignancies
A clear oncogenic role in human hematologic malignancies has been established for miR-155 and the miR-17-92 cluster (Table 1) .
MiR-155 in hematological malignancies
MiR-155 overexpression has been described both in solid and hematologic cancers. 52, 74, 75 First evidences of the oncogenic nature of this miRNA came from the observation that the final portion of the B-cell integration cluster (BIC) ncRNA accelerates MYC-mediated lymphomagenesis in a chicken model. 76 MiR-155 is located in this region of BIC, mapping in the final exon of BIC. 52 Originally identified as a common site for insertion of proviral DNA in avian leucosis virus (ALV)-induced B-cell lymphomas, BIC represents the pri-miRNA of miR-155. 46, 76, 77 High expression of precursor miR-155/BIC RNA was described in pediatric Burkitt's lymphoma (BL), 53 but not in adult primary cases of the disease, 54 probably reflecting a specific age-driven role of miR-155, substantially related to the age of onset of BL. Accumulation of miR-155/BIC RNA was detected also in other B-cell lymphomas, including diffuse large B-cell lymphomas (DLBCL), primary mediastinal B-cell lymphomas (PMBL) and Hodgkin's lymphomas. 52, 55 High levels of miR-155 are associated with the activated B-cell phenotype of DLBCL (poor prognosis), with respect to the germinal center phenotype (better prognosis), and this finding confirms the prognostic implications of miR-155 described also in solid tumors. 78 Recently high levels of miR-155 have been described also in chronic lymphocytic leukemia (CLL) cells vs normal CD19 þ B cells. 79 Despite the established biosynthetic correlation between BIC and miR-155, the mechanisms which regulate the expression of miR-155 are still unclear and deserve a better understanding. In several different cell lines, BIC transcription is induced by protein kinase C (PKC) and NF-kB, leading to an expected consensual overexpression of mature miR-155. This does not occur in Ramos and other BL cell lines, reflecting a not-betteridentified block in the processing of BIC to mature miR-155. 80 As previously described, the development of TG/KO mice models has clarified the role of miR-155 in leukemogenesis and immunity. Finally, by showing an inducible expression of miR-155 by mediators of the inflammatory response, 81 and its involvement in the response to endotoxin shock 56 a link among miRNAs, inflammation, immunity and cancer was demonstrated, offering new strategies for drug design.
MiR-17-92 cluster in hematological malignancies
The c13orf25 gene, an expressed ncRNA which harbors, in its third exon, a cluster of miRNA (the 17-92 cluster which includes miR-17-5p, -18a, -19a, -20a, -19-b-1 and -92), is located in the chromosome region 13q31-32, which frequently undergoes amplification in malignant B-cell lymphomas. 82 In analogy with the BIC/miR-155 model, the described amplification of c13orf25 in lymphomas explains the overexpression of the miR-17-92 cluster in this disease. 61, 82 The cluster constitutes the only highly evolutionary conserved portion of the c13orf25 gene, therefore suggesting that the cluster 17-92 part of the transcript harbors the oncogenic potential. In B-cell lymphoma prone MYC TG mice (which specifically overexpress the oncogene c-MYC in B-lymphocytes), an induced overexpression of this miRNAcluster (not including miR-92) dramatically accelerates lymphomagenesis and anticipates mice death. 61 While the cluster functions cooperatively with MYC to accelerate lymphoma development, individually the miRNAs of the cluster had no effect, showing the complex role of miRNA function on cancer progression. Moreover in an erythroleukemia model, the retroviral insertional activation of a murine homologue of the human c13orf25 gene (called FLI-3), which encodes for mature miRNAs derived from the miR-17-92 cluster, switches erythropoietininduced differentiation to proliferation. 83 The oncogene c-MYC directly activates the transcription of the miR-17-92 cluster. 62 More recently a BCR-ABL-c-MYC-miR-17-92 pathway has been identified, showing that expression of pri-miR-17-92 can be regulated by both BCR-ABL and c-MYC. 84 In K562 cells overexpression of the miR17-19b-1 cluster (miR-17-92 cluster without miR-92 expression) induces proliferation, confers partial resistance against inhibition of c-MYC expression, and sensitizes to imatinib-induced cell death. 84 Moreover by showing that miR-17-92 cluster is overexpressed in primary CML CD34 þ cells in chronic phase, but not in blastic crisis (with respect to normal CD34 þ cells), 84 a role for this cluster in the pathophysiology of CML can be speculated. Members of the 17-92 cluster (miR-17-5p, and miR-20a) directly downregulate the transcription factor E2F1, 62 which exerts a pro-proliferating effect in some settings, 85 and induces apoptosis in others. 86 Expression of the E2F1 gene is induced by c-MYC, 87, 88 which, in turn, can induce c-MYC by means of a positive feedback circuit. 86 By targeting E2F1, members of the miR-17-92 cluster (miR-17-5p, and miR-20a) can dampen the reciprocal activation MYC/E2F1 and tightly regulate c-MYC mediated cellular proliferation. In summary miR-17-92 cluster is oncogenic but can have tumor suppressor effects by targeting E2F1, revealing a dual nature both as OG and TSG, which depends on the set of conditions as described also for many other miRNAs. 89 Recently it has been shown that the Kis2 common retrovirus integration site on mouse chromosome X, which is responsible for radiation leukemia virus-induced T-cell leukemias, is the pri-miRNA of the miR-106-363 cluster, which represents the murine paralogue of the miR-17-92 cluster. 90 Also in human genome there are three paralogues of miR-17-92 cluster: the miR-17-92 cluster itself (on chromosome 13), the miR-106-363 cluster (on chromosome X, encoding for miR-106a, -18b, -20b, -19-b-2, -92-2 and -363) and the miR-106b cluster (on chromosome 7, encoding for miR-106b, -93 and -25). The miR-106-363 cluster is overexpressed in 46% of human T-cell leukemias. 90 In mouse, this cluster exerts an oncogenic potential by targeting MYLIP (myosin regulatory light chain-interacting protein), RBP1-LIKE (retinoblastoma-binding protein 1-like) and possibly HIPK3 (Homeodomain-interacting protein kinase 3) , 90 therefore opening intriguing questions about its close relationship with the miR-17-92 cluster.
Other oncogenic miRNAs in hematological malignancies
Together with miR-155, miR-21 and miR-221 expressions are also higher in de novo DLBCL cases with an activated B-cell phenotype with respect to the germinal center phenotype, 64 and levels of these three miRNAs have been shown to be upregulated also in follicular cell lymphoma patients, where miR-21 expression is also correlated to prognosis. 64 By analyzing the expression of miRNAs in 30 AML patients, high levels of miR-181a have been recently described in tumors with M1 or M2 morphology, compared with the samples with M4 or M5 morphology. 69 Since in normal human bone marrow, miR181a is preferentially expressed in B cells, T cells, monocytes and granulocytes, 40 which are more closely related to the M4 and M5 morphological leukemic subtypes, the observed association in myeloblastic leukemias suggests a role of miR181a in the leukemic process. Interestingly miR-181a has been recently found consistently downregulated in CLL, revealing a dual oncogenic/suppressor nature depending on the cellular context. 79 A screening of deregulated (up-and downregulated) miRNAs in ALL and CLL has recently been published, 91 providing a list of miRNA involved in leukemogenesis and of candidates for further studies aimed at determining their possible implications either as OGs or as TSGs (or both).
miRNAs as tumor suppressor genes in hematological malignancies
Among the miRNAs with a clear oncosuppressor role in hematological malignancies, we will focus on miR-15a/16-1 cluster and the miR-29 model (Table 1) .
MiR-15a/16-1 cluster in hematological malignancies
For years any investigation on the 13q14.3 region (which undergoes hemizygous and/or homozygous deletion in 450% of CLLs, therefore, representing the most frequently observed chromosomal abnormality in CLL 92 ) failed to identify any TSG which could be involved in CLL pathogenesis. The cluster encoding miR-15a and miR-16-1 was identified as mapping the 30 kb deleted region between exons 2 and 5 of the LEU2 gene, a ncRNA located in the 13q14.2 region. 93 Interestingly the cluster miR-15a/16-1 is deleted or downregulated in the majority (68%) of CLLs (with respect to CD5 þ lymphocytes from healthy donors); moreover a mutation which abolishes the expression of the cluster has been found in association with the loss of the normal allele in the leukemic cells of two CLL patients (one of whom with a familial history of CLL and breast cancer). 66 Despite the malignant, mostly nondividing B cells of CLL overexpress BCL2, 70 no known mechanism can explain how this aberrant expression occurs in the majority of cases, since only in less than 5% of cases the aberrancy is due to the juxtaposition of BCL2 to immunoglobulin loci. 94 The role of miR-15a/16-1 as TSGs in CLL was established by showing an inverse correlation between their expression and that of the antiapoptotic gene BCL2, and by showing that the cluster directly targets BCL2 in leukemic cells. 67 This finding identified the miR15a/16-1 cluster as the culprit located at 13q14.2 in CLL. Consistently with the oncosuppressor nature of miR-15a/16-1, it has been shown that miR-16-1 negatively regulates cell growth and cell-cycle progression. 95 The existence of a homologous cluster (miR-15b/16-2), located in a not commonly deleted region in CLL (3q25) raises the question about the relative contribution of the paralogous clusters in the pathogenesis of CLL. The report that CLL patients with a monoallelic 13q14 deletion have a slower lymphocyte growth kinetics than those with a biallelic deletion, 96 suggests that a residual expression of miR-15/16 could contribute to a better prognosis.
MiR-29b and 181b in hematological malignancies
MiR-29b, and miR-181b exert a tumor-suppressor function in aggressive CLL, by targeting the TCL1 oncogene. 45 TCL1 plays a critical role in the pathogenesis of CLL, as stated by its correlation with high-level expression of ZAP-70, and unmutated IgV H , both markers of aggressive CLL. 45, 97 TCL1 is a coactivator of AKT, 98, 99 an oncogene with a critical role in the regulation of many pathways involved in cell survival, proliferation and death. 100 Also, TG mice models have shown that TCL1 drives IgV-region rearrangements characteristic of the more aggressive subtype of human CLL. 101 TCL1 overexpression is also correlated with the 11q deletion, 97 another frequent chromosomal abnormality in CLL. In mouse the ectopic expression of miR-181 in hematopoietic progenitors increases the fraction of B cells in tissue culture conditions and in adult mice, 36 therefore suggesting a B-cell prodifferentiation role for miR-181. Interestingly TCL1 regulation by miR-181 represents the first example of a lymphoid-specific regulation, by means of a miRNA specifically expressed in hematopoietic cells.
Other oncosuppressor miRNAs in hematological malignancies
In acute promyelocytic leukemia, the analysis of the differentially expressed miRNAs, following treatment with the differentiating agent ATRA (all-trans-retinoic acid), showed the upregulation and revealed the potential tumor suppressor function of a group of miRNAs in this disease. 102 The group includes some known oncosuppressor miRNAs, such as miR15a, -15b and -16-1, and members of the let-7 family (namely let-7a-3, let-7c, let-7d) and miR-223, -342 and -107. By cloning small RNAs from CLL cells, Marton et al. 79 identified a consistent underexpression of miR-181a, let-7a and miR-30d. Also, miR-143 and miR-145 (downregulated in colorectal cancer 103 ) have been demonstrated to be underexpressed in a variety of B-cell malignancies, which include CLL, B-cell lymphomas, Epstein-Barr virus-transformed B-cell lines and BL cell lines. 72 The nature of this silencing is still poorly understood but does not rely on genomic aberrations or epigenetic modifications. Restoration of these two miRNAs in Raji cells exerted a dose-dependent growth inhibition effect, and was associated with downregulation of Erk5 protein (with normal levels of ERK5 mRNA), a recently characterized MAPK, most similar to the well-studied ERK1/2 subfamily. 104 Interestingly ERK5 is targeted by miR-143 and -145 both in colon cancer DLD-1 cells, 103 and in BL Raji cells, 72 therefore suggesting a wider impact of the ERK5 pathway in human carcinogenesis.
miRNAs as diagnostic and prognostic markers in hematological malignancies
The advent of high throughput methods to determine miRNA profiling in different tissues and species has led to the identification of cancer specific miRNA signatures, with diagnostic and prognostic implications. These methods include oligonucleotide miRNA microarray chips, 20 a bead-based flow cytometric miRNA method 105 and a new sensitive method for the isolation of miRNA clones, called mRAP (microRNA amplification profiling), 106 whose characteristics are summarized in Table 2 . Validation of the high throughput methods relies on northern blottings and quantitative real-time RT-PCR. Quantitative RT-PCR is based on the quantitative relationship between the amount of starting target sample and the amount of PCR product at any given cycle number. The development of looped-primers annealing to specific miRNAs and then extended by reverse transcriptase has allowed to use this technique to detect miRNA levels in a very specific and sensitive manner. 107 By studying 94 samples of CLL for which the level of expression of ZAP-70 and the mutated/unmutated IgV H status was known, a unique signature of 13 (out of 190 analyzed) miRNAs was identified. 66 This signature (Table 3) includes some of the most frequently deregulated miRNAs in different types of hematological malignancies (for example, miR-15/16, miR-29 family, miR-155, miR-221) and shows eminent prognostic implications, since the expression levels of the members of the signature correlate with CLL prognostic factors (ZAP-70 expression and IgV H mutations). 66 The bead-based flow cytometry high throughput method, applied to bone marrow samples of ALL patients, was able to accurately identify subsets of patients with different molecular pathologies (for example, T-cell ALL samples and samples with mixed lineage leukemia gene rearrangements, BCR/ABL-positive samples). 105 More recently a specific signature composed of 27 deregulated miRNAs was described as able to differentiate ALL from AML. 108 In particular four miRNAs (namely miR-128a, miR-128b, let-7b and miR-223) allow a differential diagnose of ALL vs AML with an accuracy rate of 97-99% (miR-128a and -128b upregulated in ALL vs AML; let-7b and miR-223 downregulated in ALL vs AML). 108 Interestingly lowest levels of miR-223 were described in the most immature AML phenotypes, while intermediate levels of expression were measured in the M3 (acute-promyelocytic), M4 (myelomonocytic) and M5 (monoblastic) phenotypes. 109 On the contrary, miR-181a is expressed at higher levels in M1 and M2 AMLs. 69 Although further studies are needed, the combined analysis of the expression of these miRNAs might have important diagnostic implications. A recent report from our group has identified a signature of miRNAs associated with cytogenetics and prognosis in AML. 110 By using the miRNA microarray platform, a signature of 26 downregulated miRNAs was identified in 122 newly diagnosed AML samples with respect to CD34 þ cells from 10 normal donors. Moreover miRNA expression was closely related to cytogenetic and molecular abnormalities (such as t(11q23), isolated trisomy 8 and FLT-in tandem duplication). High levels of miR-191, and miR-199a, was associated with a poor overall, and event free survival, revealing a prognostic significance for these miRNAs in AML patients.
Finally the expression of miR-155, -221 and -21 could help in the differential diagnosis between DLBCL with activated B-cell phenotype (high expression of the miRNA triad), and DLBCL with germinal center phenotype (low expression of the triad). 53, 64, 111, 112 The wide availability of the high throughput techniques and the better comprehension of the physiopathology of miRNAs in the hematological malignancies will lead to the identification of more cancer-related signatures and to a better understanding of their diagnostic and prognostic applications.
miRNAs as potential therapeutic agents
Given the existence of both tumor suppressor and oncogenic miRNAs, two possible therapeutic scenarios can be forecast in the near future: miRNAs as drugs and drugs against miRNAs.
The use of miRNAs as drugs is promising because they are endogenous regulators of cell functions, although their crossinvolvement in many different pathways needs to be better investigated to avoid the risk of undesired side effects. For instance a therapy with miR-15/16 in BCL2 positive CLLs could represent a rational therapeutic approach, albeit many pharmacologic issues still need to be addressed (for example, what is the better formulation which preserves the function of the miRNA, and allows a good pharmacodynamic profile? How to reach a tumor-specific delivery of the miRNAs?). Another strategy consists in silencing miRNAs, which are overexpressed in tumors (for example, miR-155, miR-21, miR-17-92 cluster). The availability of anti-miRNA molecules already tested to have a good half-life and efficiency in vivo (in mouse models), such as the so called 'antagomirs', 113 the anti-miRNA oligonucleotides, 114 and the locked nucleic acid-modified oligonucleotides 115 has already allowed to investigate the effects of oncogenic miRNA silencing in preclinical models, giving the rationale for further clinical studies. In addition, or alternatively, a combination of miRNAs and chemotherapy is also being investigated and has already shown interesting results: miR-21 overexpression improves the response to gemcitabine in cholangiocarcinoma cells, 116 whereas silencing of miR-98 could reverse the resistance to doxorubicin in refractory hypoxic Table 2 Main properties of some of the most used miRNA high-throughput methods 117 Finally the impact of drug administration on miRNA expression represents another promising therapeutic approach. Despite its location in the largest miRNA cluster identified to date (on human chromosome 14q32.31), miR-127, which is normally silenced in cancer cells, is specifically and selectively re-expressed after treatment with a DNA-demethylating agent (5-aza-2 0 -deoxycytidine) and a histone deacetylase inhibitor (4-phenylbutyric acid). 118 After its re-activation, miR-127 exerts its TSG's role by targeting the oncogene BCL6. 118 A recent study has identified upregulation of oncogenic miRNAs (such as the miR-17-92 cluster, miR-106a and miR-34) in the liver of Fisher 344 rats, after long-term tamoxifen exposure, showing a possible side effect of a prolonged and well established hormonotherapy. 119 In summary whether used as drugs or induced by drugs, miRNAs harbor promising as well as dangerous implications. In particular, the dual nature of some miRNAs, both as oncogenes and as TSGs, 89 imposes a better characterization of the specific conditions (miRNA dose, cell/tissue specificity, concomitant expression of other miRNAs/macromolecules, and so on) that affect the switch toward an oncogenic or oncosuppressor phenotype, in order to manage them for therapeutic purposes. The full comprehension of the functions of a miRNA (or of a group of miRNAs) constitutes the condicio sine qua non for the development of any miRNA-based drug. The exponential increase in the number of publications on miRNAs reflects the efforts of many different research groups in clarifying the pathophysiology of miRNAs in cancer (and other human diseases), and justify some optimism about the possible development of miRNA-based therapies in a not so far away future.
Method

Other ncRNAs in hematological malignancies
Other ncRNAs appear to be involved in hematological malignancies. Recently we were able to demonstrate that UCRs are also frequently located at CAGRs, and that UCRs differentially expressed in human cancers are located in CAGRs specifically correlated to that type of cancer. 21 Despite no mutations being described in the protein coding genes of the chromosomal region 13q21.33-q22.2 (linked to susceptibility to familial CLL 74 ), two UCRs (uc.349A(P) and uc.352(N)) are part of a cluster of seven UCRs located in this CAGRs, and are differentially expressed between normal and malignant B-CLL CD5-positive cells. 21 These UCRs could be responsible for the inheritance of this familial malignancy in these specific families. By investigating UCR expression in 173 samples (133 human cancers and 40 corresponding normal tissues) a different hierarchical clustering of the samples was found, based on the different developmental origin of the tumors, and that specific groups of UCGs are differentially expressed in tumor types, defining a tumor-specific signature of UCGs. 21 In CLL the signature is composed of 19 UCGs (some of which are listed in Table 1 ), 8 of which upregulated and 11 downregulated with respect to the corresponding normal control (CD5 þ B cells from six healthy individuals). 21 Interestingly among the downregulated UCRs in CLL there is UC.73A(P) which we demonstrated acting as an oncogene (its silencing leads to apoptosis) in colorectal cancer cell lines, where the same UCR is strongly upregulated. 21 The opposite deregulation observed in two different types of cancer suggests a possible tumor-specific function for this UCR.
Conclusions
Increasing evidences suggest a role of miRNAs in hematological malignancies. A better understanding of the physiological functions of miRNAs in hematopoiesis represents the necessary background to interpret the aberrancies of expression described in the malignant phenotype. The recent discovery that other ncRNAs (namely UCGs) play a role in human cancers, and that between miRNAs and UCGs reciprocal regulatory mechanisms exist, 21 opens new insights in the interpretation of human cancers, gives rationale to the development of new diagnostic and prognostic tools, and to the identification of new promising therapeutic strategies.
